Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Phase of Trial: Phase III
Latest Information Update: 06 Oct 2019
Price : $35 *
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors United Therapeutics Corporation
- 31 Jan 2019 According to an United Therapeutics Corporation media release, additional risk of mortality data accrued in this open-label extension study was also part of results presented at the Pulmonary Vascular Research Institute Annual World Congress on Pulmonary Vascular Disease in Barcelona, Spain.
- 13 Oct 2017 This study has been completed in Austria as per European Clinical Trials Database.
- 12 Feb 2015 Planned number of patients changed from 858 to 610 as reported by ClinicalTrials.gov record.